☰

William A. Freed-Pastor, Ph.D. - Publications

Affiliations: 
Biological Sciences Columbia University, New York, NY 
Area:
p53 tumour suppressor protein
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, et al. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. PMID 30580964 DOI: 10.1016/J.Cell.2018.11.011  0.714
2018 Rastogi C, Rube HT, Kribelbauer JF, Crocker J, Loker RE, Martini GD, Laptenko O, Freed-Pastor WA, Prives C, Stern DL, Mann RS, Bussemaker HJ. Accurate and sensitive quantification of protein-DNA binding affinity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29610332 DOI: 10.1073/Pnas.1714376115  0.65
2017 Kribelbauer JF, Laptenko O, Chen S, Martini GD, Freed-Pastor WA, Prives C, Mann RS, Bussemaker HJ. Quantitative Analysis of the DNA Methylation Sensitivity of Transcription Factor Complexes. Cell Reports. 19: 2383-2395. PMID 28614722 DOI: 10.1016/J.Celrep.2017.05.069  0.664
2017 Freed-Pastor W, Prives C. Targeting mutant p53 through the mevalonate pathway. Nature Cell Biology. 18: 1122-1124. PMID 27784901 DOI: 10.1038/Ncb3435  0.638
2015 Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes & Development. 29: 1298-315. PMID 26080815 DOI: 10.1101/Gad.263202.115  0.653
2015 Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T, Manfredi J, Simon I, Prives C. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Molecular Cell. 57: 1034-46. PMID 25794615 DOI: 10.1016/J.Molcel.2015.02.015  0.563
2012 Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes & Development. 26: 1268-86. PMID 22713868 DOI: 10.1101/Gad.190678.112  0.65
2012 Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148: 244-58. PMID 22265415 DOI: 10.1016/J.Cell.2011.12.017  0.713
2011 Freed-Pastor WA, Prives C. Dissimilar DNA binding by p53 in normal and tumor-derived cells. Cell Cycle (Georgetown, Tex.). 10: 4207. PMID 22127203 DOI: 10.4161/Cc.10.24.18723  0.686
2007 Kass EM, Ahn J, Tanaka T, Freed-Pastor WA, Keezer S, Prives C. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. The Journal of Biological Chemistry. 282: 30311-21. PMID 17715138 DOI: 10.1074/Jbc.M704642200  0.699
Show low-probability matches.